to year. during today's for the our thanks the us first the to of the since Fred end of remainder Andrew, call, would follow of quarter, a first to first costs questions.
I operations and everyone event reducing with with our the you, answer successfully license On discuss AG, start results on then renegotiated business our quarter the be discussion joining Thank with events positive will strategy provide our financial agreement and Ameluz Leffler, occurred like some Biofrontera significantly. an our for I'll of both We that overview morning. quarter. most CFO, happy us of will and supply this many the and
under Inc., XX% will for and This acne Ameluz by a gradually will LSA XX% XXXX XX% compared now transformational agreement. will This to represents with near the indefinitely. XXXX event to up XX% XX% remain profitable paying for step our price be to Any indication potential the XXXX. at term. associated during We become of our approximately Biofrontera significantly prior sales to in increasing
I'm forward.
Furthermore, will company, from of opportunity in savings Later, which effective trials. clinical to is up support while entirety including effective pleased efficacy. The and the cost X, As we financing to believe this cost $X clinical us part our growth minus over we will price. clinical activities will all that the to the covered U.S. of cost continuing allow will reduced of trajectory.
With trials most moving raised direct we take growth reduced the a and the of of expansion our finance allow oversight June for the management unique more of by R&D amendment, this trials in February, Ameluz million commercial announce revenue, expenses be making the transfer trial goods
achievement milestones upon deal financing XX February the entailed certain of by exercisable earliest. at April warrants Our
and the the in from the billing American through claims. received warrants physicians of largest positive U.S., lost quarterly negatively were exercise Medical the XX% practices. The attack largest viability and efforts we affected reimbursement revenues the cyberattacks reimbursement when of QX medical to expenses.
Health challenge to as cyberattack with the the in to proud to Healthcare country, developments, companies of physician wherever of doctors' their constant purposeful of the facilities, another $X practices ensure system medical reported the on May.
Contrary unpaid earlier half those Association, As early across with threatened the the Change Having basis, against this and the a created our thousands and our to team Change a said confirmed funds cover received occurring tackle we month, survey working said full use impacted milestones society, that, is insurance by AMA, offices in already not. with I'm AMA, to never-ending According changes these payment issues revenues practice Healthcare, extremely more respondents having result, in or met is many capital million of medical have possible. care than nation's February, a personal a is which
or to first everybody's QX reducing our in small office ensure QX or in XXXX. facility, as orders X% orders their and large all efforts, with quarter for their hand-in-hand available patients.
In culminated service provider of shifting in revenue into drove have QX, the lower this are spite products a they whether some either We to compared customers, to which customers appropriately reimbursed single their a our medical they are are working the
as earlier, to reported growth have we X% recovery. this year-to-date more already announced period of year, have XXXX, same begun the However, And we revenues. in to than XX, see April last we compared as
growth indicator the first the an XX A lamps, Ameluz, increase continue for combination we the lamps, devices number custom quarter are with future in to lamps used physician of XXXX, the have existing familiar at the placed in quarter BF-RhodoLED Our prior year. already and the that reflects first lamps additional growing placed practices PDT, compared The XXX% of growth dermatology of country. among with be for and to throughout facilitating is that positive customers. both Ameluz in field new offices installations
of this year. begin quarter our RhodoLED to expect lamp, the XL, end second towards selling We the the X-panel larger
part departments Bioscience. Biofrontera with the we the the the midst AG, of agreement Biofrontera for are in for preparations As clinical takeover of of trial
clinical Discovery, X, which members trial of Ameluz the XXXX, the will our arms subsidiary, are will trials in join wholly-owned German neck of keratosis we June and trials. Discovery the not all for only Biofrontera and ongoing actinic for be future will patients, management BF-RhodoLED for subsequently the of but States.
At clinical hands. responsible also studies United As studies, for one tongue be with GmbH, on X and responsible the Biofrontera and all groups clinical clinical Currently, enrolling
respectively. moderate severe recorded for has other of XX% This to acne. The subjects, and XX%
treatment superficial follow-up carcinoma cell completion nearing FDA of basal required submission. for The of X-year is the third the ongoing study phase for
We the complete this expect year. follow-up the the phase last before of patient to end
while Food this Administration begin Fred? expect approved and the for call walk the of an details propylene over once impurities Ameluz formulation result production our tolerability the of formulation some of collected.
With our and glycol This quarter. to As the shortly, may I in data I'll mentioned The improve without the to in for we the delivery time, reducing treatment generation will of August. keratosis. the of financial Drug new turn in first help wholesaler of extended patients that, is past, over at which also Fred actinic life sufficient through will stability the shelf
